From AI diagnostics to exoskeletons, the event highlights how healthcare tech is moving into real-world use
Updated
April 8, 2026 10:43 AM
Tesla Bot Optimus, designed by Tesla. PHOTO: ADOBE STOCK
The China International Medical Equipment Fair 2026 will open in Shanghai from April 9 to 12 at the National Exhibition and Convention Center. It is one of the largest gatherings in the medical device industry. This year’s edition will cover more than 320,000 square metres. Nearly 5,000 companies and brands are expected to participate, representing over 20 countries and regions. Organisers also expect more than 200,000 professional visitors and buyers from around 150 markets.
A key focus this year is the growing use of artificial intelligence in healthcare. One of the headline technologies is an AI agent designed to carry out multiple diagnoses from a single scan. The exhibition will also feature diagnostic software that is already in clinical use. In addition, an integrated platform for AI training and inference will be showcased to improve computing capacity within healthcare institutions.
Robotics will also play a central role at the event. New systems across surgical procedures, rehabilitation and elderly care are expected to be presented. Together, these developments point to a steady move toward more precise and assisted forms of care. Many of these technologies are designed to support clinicians and patients, especially in tasks that require consistent accuracy or long-term physical assistance.
For the first time, the event will introduce a dedicated Future Tech Arena. It will focus on brain-computer interfaces, embodied intelligence and university-led innovation. The space will include AI-assisted MRI systems for Alzheimer’s diagnosis. It will also feature brain-computer interface technologies used for cognitive assessment and training, along with wearable robotic exoskeletons.
Alongside product showcases, the event will continue to act as a platform for international trade and collaboration. An International Zone will host exhibitors from countries such as the United States, Germany, Japan, South Korea, the United Kingdom, France, Singapore, Malaysia and Thailand. This provides a view of how different markets are approaching medical technology. It also reflects the global nature of innovation and deployment in this sector.
The programme will include a set of networking and exchange formats under its “We” initiative. These include discussion stages with representatives from consulates and industry organisations, as well as matchmaking sessions based on verified buyer demand. Guided tours will also be organised to help international visitors connect with relevant exhibitors. In parallel, organisers are working with hospital partners to provide medical support services for attendees during the event.
Across the four days, hundreds of forums are scheduled. These will bring together policymakers, researchers and industry leaders to discuss regulatory frameworks, market access and the future of healthcare innovation. Some of these sessions will be led by the Global Harmonization Working Party in collaboration with the Ministry of Health of Malaysia, with a focus on regulatory alignment and cross-border cooperation in medical devices.
As healthcare systems continue to adopt digital tools and advanced equipment, events like CMEF provide a clear view of how these technologies are being developed and applied. The scale of participation this year reflects continued activity across both innovation and international collaboration in the medical device sector.
Keep Reading
Examining the shift from fast answers to verified intelligence in enterprise AI.
Updated
January 8, 2026 6:33 PM
Startup employee reviewing business metrics on an AI-powered dashboard. PHOTO: FREEPIK
Neuron7.ai, a company that builds AI systems to help service teams resolve technical issues faster, has launched Neuro. It is a new kind of AI agent built for environments where accuracy matters more than speed. From manufacturing floors to hospital equipment rooms, Neuro is designed for situations where a wrong answer can halt operations.
What sets Neuro apart is its focus on reliability. Instead of relying solely on large language models that often produce confident but inaccurate responses, Neuro combines deterministic AI — which draws on verified, trusted data — with autonomous reasoning for more complex cases. This hybrid design helps the system provide context-aware resolutions without inventing answers or “hallucinating”, a common issue that has made many enterprises cautious about adopting agentic AI.
“Enterprise adoption of agentic AI has stalled despite massive vendor investment. Gartner predicts 40% of projects will be canceled by 2027 due to reliability concerns”, said Niken Patel, CEO and Co-Founder of Neuron7. “The root cause is hallucinations. In service operations, outcomes are binary. An issue is either resolved or it is not. Probabilistic AI that is right only 70% of the time fails 30% of your customers and that failure rate is unacceptable for mission-critical service”.
That concern shaped how Neuro was built. “We use deterministic guided fixes for known issues. No guessing, no hallucinations — and reserve autonomous AI reasoning for complex scenarios. What sets Neuro apart is knowing which mode to use. While competitors race to make agents more autonomous, we're focused on making service resolution more accurate and trusted”, Patel explained.
At the heart of Neuro is the Smart Resolution Hub, Neuron7’s central intelligence layer that consolidates service data, knowledge bases and troubleshooting workflows into one conversational experience. This means a technician can describe a problem — say, a diagnostic error in an MRI scanner — and Neuro can instantly generate a verified, step-by-step solution. If the problem hasn’t been encountered before, it can autonomously scan through thousands of internal and external data points to identify the most likely fix, all while maintaining traceability and compliance.
Neuro’s architecture also makes it practical for real-world use. It integrates seamlessly with enterprise systems such as Salesforce, Microsoft, ServiceNow and SAP, allowing companies to embed it within their existing support operations. Early users of Neuron7’s platform have reported measurable improvements — faster resolutions, higher customer satisfaction and reduced downtime — thanks to guided intelligence that scales expert-level problem solving across teams.
The timing of Neuro’s debut feels deliberate. As organizations look to move past the hype of generative AI, trust and accountability have become the new benchmarks. AI systems that can explain their reasoning and stay within verifiable boundaries are emerging as the next phase of enterprise adoption.
“The market has figured out how to build autonomous agents”, Patel said. “The unsolved problem is building accurate agents for contexts where errors have consequences. Neuro fills that gap”.
Neuron7 is building a system that knows its limits — one that reasons carefully, acts responsibly and earns trust where it matters most. In a space dominated by speculation, that discipline may well redefine what “intelligent” really means in enterprise AI.